Glycemic variability correlates strongly with postprandial β-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents

Diabetes Care

Volumn 32, Issue 6, 2009, Pages 1058-1062

  Kohnert, Klaus Dieter ^a   Augstein, Petra ^a   Zander, Eckhard ^b   Heinke, Peter ^a   Peterson, Karolina ^a   Freyse, Ernst Joachim ^a   Hovorka, Roman ^c   Salzsieder, Eckhard ^a  

^a Institut fur Diabetes 'Gerhardt Katsch'   (Germany)

^b Clinics for Diabetes and Metabolic Diseases   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CARBOHYDRATE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CARBOHYDRATE INTAKE; CELL FUNCTION; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; OXIDATIVE STRESS; POSTPRANDIAL PERIOD; SULFONYLUREA COMPOUNDS;

EID: 66549089200     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1956     Document Type: Article

References (25)

1. Turner RC, Holman RR, Cull CA, Stratton IM, Mattthews RR, Frighi V, Manley E, Neil A, McElroy H, Wright D, Kohner E, Fox C, Hadden D. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
2. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients - variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-885 (Pubitemid 36929359)
3. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7
4. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
5. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708
6. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004;279:42351-42354
7. 1c in Japanese type 2 diabetic patients. Diabetes Care 2005;28:2806-2807
8. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Study. J Clin Endocrinol Metab 2006;91:813-819 (Pubitemid 43357744)
9. Del PS, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002;51 (Suppl. 1):S109-S116 (Pubitemid 34761504)
10. Service FJ, Nelson RL. Characteristics of glycemic stability. Diabetes Care 1980;3:58-62 (Pubitemid 10079157)
11. Haupt E, Etti H, Bamberg J, Hilgenfeld J, Schöffling K: Blutzuckersenkende Sulfonamide: Eine Placebo-Auslassstudie zur Objektivierung der Wirsamkeit oraler Antidiabetika. Akt Endokrinol Stoffw 1984;5:23-31 [article in German] (Pubitemid 14175660)
12. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003;26:977-980 (Pubitemid 36929234)
13. Schrezenmeir J, Fenselau S, Keppler I, Abel J, Orth B, Laue C, Sturmer W, Fauth O, Halmagyi M. Postprandial triglyceride high response and the metabolic syndrome. Ann N Y Acad Sci 1997;827:353-368 (Pubitemid 27480278)
14. 1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 2000;77:420-426
15. Postprandial blood glucose. American Diabetes Association. Diabetes Care 2001;24:775-778 (Pubitemid 32888866)
16. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-655
17. Hovorka R, Chassin L, Luzio SD, Playle R, Owens DR. Pancreatic β-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:744-750 (Pubitemid 28496439)
18. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495 (Pubitemid 38680001)
20. 1c level. Diabetes Care 2000;23:1830-1834
21. Cremer GM, Molnar GD, Taylor WF, Moxness KE, Service FJ, Gatewood LC, Ackerman E, Rosevear JW. Studies of diabetic instability. II. Tests of insulinogenic reserve with infusions of arginine, glucagon, epinephrine, and saline. Metabolism 1971;20:1083-1098
22. Monnier L, Colette C. Glycemic variability - should we and can we prevent it? Diabetes Care 2008;31:S150-S154
23. Albarrak AI, Luzio SD, Chassin LJ, Playle RA, Owens DR, Hovorka R. Associations of glucose control with insulin sensitivity and pancreatic β-cell responsiveness in newly presenting type 2 diabetes. J Clin Endocrinol Metab 2002;87:198-203 (Pubitemid 34084691)
24. Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoffman RM. Sources of glucose variability in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Clin Endocrinol (Oxf) 2004;60:451-456 (Pubitemid 38482507)
25. Bloomgarden ZT. Exploring treatment strategies for type 2 diabetes. Diabetes Care 2007;30:2737-2745 (Pubitemid 47547829)